Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Institutional Investors Reassess Positions in Evolv Technologies

Dieter Jaworski by Dieter Jaworski
December 15, 2025
in Analysis, Cyber Security, Earnings, Nasdaq, Tech & Software
0
Evolv Technologies Holdings Stock
0
SHARES
15
VIEWS
Share on FacebookShare on Twitter

The investment landscape surrounding Evolv Technologies Holdings is currently marked by significant portfolio adjustments from major funds, alongside a mixed pattern of insider transactions. The stock opened its most recent trading session at $7.01 per share, prompting analysis of its potential trajectory.

Financial Performance and Market View

Evolv reported third-quarter fiscal 2025 results that surpassed market expectations. The company posted a loss per share of ($0.01), notably better than the anticipated ($0.07). Revenue came in at $42.85 million, exceeding estimates of $33.73 million. Despite this outperformance, key financial metrics remain challenging, with a return on equity of -55.11% and a net margin of -43.76%. Analyst consensus currently rates the stock as a “Moderate Buy,” with an average 12-month price target of $9.13. Projections for the ongoing fiscal year suggest an earnings per share of -0.27.

A Closer Look at Fund Activity

Recent regulatory filings reveal a period of active repositioning by institutional investors, indicating a sector-wide reassessment rather than a uniform directional bet.

Several firms established or substantially increased their stakes. GatePass Capital acquired 150,000 shares valued at approximately $936,000 during the second quarter, bringing its ownership to about 0.09% of the company. Similarly, Metavasi Capital initiated a new position, purchasing 781,048 shares worth around $4.87 million, equivalent to a 0.48% stake.

More substantial buying activity was recorded by major asset managers. Vanguard Group increased its holdings by 5.3%, bringing its total to 9,402,716 shares valued at roughly $29.34 million. Marshall Wace boosted its position by a significant 74.4%, now holding 3,899,155 shares worth $24.33 million. Invesco Ltd. executed the most dramatic percentage increase, growing its stake by 1,080.6% to 517,886 shares, a $3.23 million investment.

Should investors sell immediately? Or is it worth buying Evolv Technologies Holdings?

Conversely, FourWorld Capital Management reduced its exposure, selling 581,540 shares in Q2 for a 26.6% decrease. It retains a holding of 1,606,563 shares, representing approximately 0.98% of Evolv.

Insider Trading and Stock Price Dynamics

Transactions by company executives show a nuanced picture. Directors Kevin M. Charlton and Richard A. Shapiro recently increased their direct holdings by 15,000 and 16,300 shares, respectively. Over the preceding 90-day period, insider activity netted a purchase of 61,300 shares, though this was offset by sales totaling 440,745 shares. Insiders collectively control 11.30% of the company’s outstanding shares.

The stock closed at $7.01 on December 12 on a trading volume of 3,601,978 shares, moving between an intraday low of $6.78 and a high of $7.04. Key technical levels place the 50-day moving average at $7.11 and the 200-day average at $6.96. Over the past year, the share price has demonstrated considerable volatility, trading within a range of $2.64 to $8.91. This has translated to a strong twelve-month total return of 86.93%, with a year-to-date gain of 76.57%.

Forward-Looking Catalysts

Market participants are looking to upcoming corporate engagements for fresh insight. Evolv is scheduled to present at the Northland Virtual Growth Conference. Commentary from management regarding margin improvement or revenue growth trends during such events could provide actionable catalysts for the stock’s near-term direction. The company’s ability to translate top-line beats into sustained profitability will likely remain a central focus for investors.

Ad

Evolv Technologies Holdings Stock: Buy or Sell?! New Evolv Technologies Holdings Analysis from March 25 delivers the answer:

The latest Evolv Technologies Holdings figures speak for themselves: Urgent action needed for Evolv Technologies Holdings investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Evolv Technologies Holdings: Buy or sell? Read more here...

Tags: Evolv Technologies Holdings
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Gossamer Bio Stock
Analysis

Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026

March 25, 2026
SOXX ETF Stock
Commodities

Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns

March 25, 2026
Fair Isaac Stock
Analysis

Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

March 25, 2026
Next Post
Renesola Stock

Renesola Completes Privatization, Exits Public Markets

Uranium Energy Stock

Uranium Energy Shares: Market Pessimism Meets Analyst Conviction

Broadcom Stock

Broadcom Shares Tumble Despite Record Quarterly Performance

Recommended

Lockheed Martin Stock

Defense Giant Lockheed Martin Secures Billions in New Military Contracts

6 months ago
OKE stock news

Amalgamated Bank Increases Stake in CF Industries as Market Opinions Vary

3 years ago
IBM Stock

IBM’s AI Windfall Fails to Impress Stock Market

7 months ago
Blackstonecured Lending Fund Stock

Blackstone BDC Insider Purchase Defies Analyst Downgrades

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Figma Embraces Third-Party AI to Power Its Design Ecosystem

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

Evolent Health Bets on AI Leadership Amid Share Price Decline

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Trending

Gossamer Bio Stock
Analysis

Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026

by Kennethcix
March 25, 2026
0

The future of Gossamer Bio hinges on a critical regulatory discussion scheduled for June 2026. The biopharmaceutical...

SOXX ETF Stock

Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns

March 25, 2026
Fair Isaac Stock

Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

March 25, 2026
Figma Stock

Figma Embraces Third-Party AI to Power Its Design Ecosystem

March 25, 2026
BioNano Genomics Stock

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026
  • Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns
  • Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com